Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash & Equivalents (2019 - 2025)

Allogene Therapeutics' Cash & Equivalents history spans 7 years, with the latest figure at $37.8 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 26.2% year-over-year to $37.8 million; the TTM value through Sep 2025 reached $37.8 million, down 26.2%, while the annual FY2024 figure was $75.2 million, 9.54% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $37.8 million at Allogene Therapeutics, down from $50.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $176.6 million in Q1 2021 and bottomed at $11.8 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $83.2 million (2023), against an average of $92.6 million.
  • The largest annual shift saw Cash & Equivalents plummeted 89.85% in 2022 before it skyrocketed 607.1% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $115.9 million in 2021, then tumbled by 89.85% to $11.8 million in 2022, then surged by 607.1% to $83.2 million in 2023, then dropped by 9.54% to $75.2 million in 2024, then plummeted by 49.73% to $37.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Cash & Equivalents are $37.8 million (Q3 2025), $50.8 million (Q2 2025), and $42.5 million (Q1 2025).